Aspirin for primary prevention of cardiovascular disease
- 1 September 2018
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 392 (10152) , 988-990
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trialThe Lancet, 2018
- Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trialsThe Lancet, 2018
- Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes MellitusCirculation, 2016
- Aspirin and CancerJACC, 2016
- Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task ForceAnnals of Internal Medicine, 2016
- Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation StatementAnnals of Internal Medicine, 2016
- Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task ForceAnnals of Internal Medicine, 2016
- 2016 European Guidelines on cardiovascular disease prevention in clinical practiceEuropean Heart Journal, 2016
- Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery DiseaseCirculation: Cardiovascular Interventions, 2011
- Low-Dose Aspirin for the Prevention of AtherothrombosisNew England Journal of Medicine, 2005